<DOC>
	<DOCNO>NCT00946595</DOCNO>
	<brief_summary>A 2-year multicenter , phase II/III , randomize active-controlled trial evaluate efficacy tolerance two maintenance strategy HIV-1 infect patient HIV RNA 50 copies/mL : monotherapy lopinavir/ritonavir single-tablet triple therapy ( EFV/FTC/TDF ) .</brief_summary>
	<brief_title>Evaluation Lopinavir/Ritonavir Monotherapy v Triple Therapy Maintenance Regimens HIV-1 Infected Patients</brief_title>
	<detailed_description>Today , one challenge HIV treatment overcome side effect toxicity long term antiretroviral therapy . A promising approach may simplification treatment maintenance strategy , spar certain antiretroviral drug class . This two-year prospective phase II/III , multicenter randomize trial evaluate efficacy tolerance lopinavir/ritonavir monotherapy maintenance regimen HIV-infected adult . Enrolled patient must stable antiretroviral treatment HIV-1 RNA 50 cp/mL previous 12 month , prior treatment failure . Provided informed consent , 420 patient randomize 1:1 ratio two open-label treatment group receive either lopinavir/r 800/200mg per day EFV/FTC/TDF 600/200/245 mg per day ( fix dose combination ) . The main objective ass treatment efficacy tolerance 2 year . In 80 patient , repeat DEXA measurement perform trial order evaluate change bone mineral density body composition .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Confirmed HIV1 infection Stable antiretroviral treatment 6 month HIV1 RNA &lt; 50 cp/mL least 12 month Lymphocytes CD4+ &gt; 200/mm3 Lymphocytes CD4+ nadir &gt; 100/mm3 Absence prior treatment failure ( define two successive HIV1 RNA â‰¥ 50 cp/mL NNRTI PI treatment ) Absence documentation mutation confer NRTI NNRTI resistance primary mutation protease gene Written inform consent Patient affiliate social security scheme Woman child bear potential without efficient contraception Pregnant breastfeed woman HBV infection ( HbS Ag+ ) HBC infection require specific treatment trial Liver cirrhosis ChildPugh C HIV1/HIV2 Coinfection isolate HIV2 infection Ongoing interleukin interferon treatment Coadministration contraindicate treatment Hypersensibility efavirenz lopinavir/r Absolute neutrophil count &lt; 750/mm3 , hemoglobin &lt; 8g/dL , platelet &lt; 60.000/mm3 , creatinine clearance &lt; 50 mL/min , ASAT , ALAT , lipase , alkaline phosphatase total bilirubin &gt; 3 ULN , CD4 nadir &lt; 100/mm3 . Participation another clinical trial interfere study drug assignment DREAM Subject legal guardianship incapacitation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Undetectable</keyword>
	<keyword>HIV infection</keyword>
	<keyword>Monotherapy</keyword>
	<keyword>Lopinavir/ritonavir</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>Treatment experience</keyword>
</DOC>